Previous clinical trials and meta-analyses have confirmed the effectiveness of SGLT-2 inhibitors in the prevention of HF [2] and the improvement in prognosis by SGLT-2 inhibitors is independent of the type of HF [3]. Here, SLC5A2 is linked to hydrops fetalis.